← All stories
Markets
STAT+: Pharmalittle: We’re reading about an FDA rejection, 340B court battles, and more
The FDA rejected a radiopharmaceutical therapy because of manufacturing issues, halting what would have been a competitor for Novartis
Covered by 1 outlet
All coverage · 1 article